Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: AGN002
MIFTS: 55

Agnosia

Categories: Mental diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Agnosia

About this section

MalaCards integrated aliases for Agnosia:

Name: Agnosia 11 19 52 43 14 16 71 75 31
Primary Visual Agnosia 19 71
Dyspraxia 11 5
Monomodal Visual Amnesia 19
Agnosia, Primary Visual 75
Dyspraxia Syndrome 11
Visual Amnesia 19
Apraxias 71
Alexia 71

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:4090
MeSH 43 D000377
NCIt 49 C84542
SNOMED-CT 68 42341009
ICD10 31 R48.1
UMLS 71 C0001816 C0002018 C0003635 more
Sources

Summaries for Agnosia

About this section

NINDS: 52 Agnosia is a rare disorder characterized by an inability to recognize and identify objects or persons. People with agnosia may have difficulty recognizing the geometric features of an object or face or may be able to perceive the geometric features but not know what the object is used for or whether a face is familiar or not. Agnosia can be limited to one sensory modality such as vision or hearing. For example, a person may have difficulty in recognizing an object as a cup or identifying a sound as a cough. Agnosia can result from strokes, dementia, developmental disorders, or other neurological conditions. It typically results from damage to specific brain areas in the occipital or parietal lobes of the brain. People with agnosia may retain their cognitive abilities in other areas.

MalaCards based summary: Agnosia, also known as primary visual agnosia, is related to pain agnosia and amnestic disorder, and has symptoms including fever, dyspnea and vertigo. An important gene associated with Agnosia is SIL1 (SIL1 Nucleotide Exchange Factor), and among its related pathways/superpathways are GPCR downstream signalling and Signal Transduction. The drugs Benzocaine and Tannic acid have been mentioned in the context of this disorder. Affiliated tissues include temporal lobe, brain and cortex, and related phenotypes are nervous system and homeostasis/metabolism

GARD: 19 Agnosia is characterized by an inability to recognize and identify objects and/or persons. Symptoms may vary, according to the area of the brain that is affected. It can be limited to one sensory modality such as vision or hearing; for example, a person may have difficulty in recognizing an object as a cup or identifying a sound as a cough. Agnosia can result from strokes, traumatic brain injury, dementia, a tumor, developmental disorders, overexposure to environmental toxins (e.g., carbon monoxide poisoning), or other neurological conditions. Visual Agnosia may also occur in association with other underlying disorders. People with Agnosia may retain their cognitive abilities in other areas.

Disease Ontology: 11 A communication disorder that is a loss of ability to recognize objects, persons, sounds, shapes, or smells while the specific sense is not defective nor is there any significant memory loss.

Wikipedia 75 Agnosia: Agnosia is the inability to process sensory information. Often there is a loss of ability to recognize... more...

Agnosia, primary visual: Visual agnosia is an impairment in recognition of visually presented objects. It is not due to a deficit... more...
Sources

Related Diseases for Agnosia

About this section

Diseases in the Agnosia family:

Form Agnosia

Diseases related to Agnosia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 391)
# Related Disease Score Top Affiliating Genes
1 pain agnosia 31.8 TRPV1 TRPA1 TCF21 TAC1 SCN9A SAG
2 amnestic disorder 31.0 PDYN OXT OPRM1 FOS
3 speech and communication disorders 30.7 TAC1 POMC OXT OPRM1 LIPN IL6
4 attention deficit-hyperactivity disorder 30.7 TAC1 POMC PDYN OXT OPRM1 IL6
5 neurogenic bladder 30.3 TRPV1 TAC1 CALCA
6 psychotic disorder 30.2 PDYN OXT OPRM1 IL6 FOS
7 complex regional pain syndrome 30.0 TRPV1 TRPA1 TAC1 SCN9A OPRM1 IL6
8 paine syndrome 29.9 TRPV1 TRPA1 TAC1 SCN9A POMC PNOC
9 anxiety 29.9 TRPV1 TAC1 POMC PNOC PDYN OXT
10 visual agnosia 11.6
11 apperceptive agnosia 11.6
12 auditory agnosia 11.6
13 social emotional agnosia 11.5
14 finger agnosia 11.5
15 integrative agnosia 11.5
16 rolandic epilepsy, impaired intellectual development, and speech dyspraxia, x-linked 11.5
17 tactile agnosia 11.4
18 neurodevelopmental disorder with intention tremor, pyramidal signs, dyspraxia, and ocular anomalies 11.4
19 childhood apraxia of speech 11.4
20 form agnosia 11.3
21 color agnosia 11.3
22 topographical agnosia 11.3
23 associative agnosia 11.3
24 astereognosia 11.3
25 verbal auditory agnosia 11.3
26 developmental dyspraxia 11.3
27 mirror agnosia 11.3
28 rolandic epilepsy-speech dyspraxia syndrome 11.3
29 time agnosia 11.3
30 semantic agnosia 11.2
31 visual verbal agnosia 11.2
32 gerstmann syndrome 11.2
33 autotopagnosia 11.2
34 phonagnosia 11.2
35 prosopagnosia 11.2
36 cortical deafness 11.1
37 developmental coordination disorder 11.1
38 kluver-bucy syndrome 11.1
39 isolated childhood apraxia of speech 11.1
40 apraxia 11.0
41 alexia 11.0
42 craniofacial dyssynostosis with short stature 11.0
43 marbach-schaaf neurodevelopmental syndrome 11.0
44 polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1 11.0
45 spastic paraplegia 14, autosomal recessive 11.0
46 agraphia 11.0
47 foxp2-related speech and language disorders 11.0
48 galactosemia i 10.9
49 amusia 10.9
50 dysphasia, familial developmental 10.9

Graphical network of the top 20 diseases related to Agnosia:



Diseases related to Agnosia
Sources

Symptoms & Phenotypes for Agnosia

About this section

UMLS symptoms related to Agnosia:


fever; dyspnea; vertigo; cachexia; abnormality of extrapyramidal motor function; headache; syncope; scanning speech; cyanosis; edema; clumsiness; torticollis; visual agnosia; icterus; seizures; signs and symptoms; signs and symptoms, digestive; other symbolic dysfunction; hot flushes; muscle rigidity; symptoms

MGI Mouse Phenotypes related to Agnosia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.31 CALCA FAAH FOS IL6 OPRK1 OPRL1
2 homeostasis/metabolism MP:0005376 10.16 CALCA FAAH FOS IL6 LIPN OPRK1
3 normal MP:0002873 10.09 CALCA FAAH FOS OPRL1 OPRM1 SCN9A
4 renal/urinary system MP:0005367 9.97 CALCA IL6 OXT POMC SCN9A TAC1
5 adipose tissue MP:0005375 9.97 FOS IL6 OPRM1 OXT PDYN POMC
6 growth/size/body region MP:0005378 9.97 FOS IL6 OPRL1 OPRM1 OXT PDYN
7 behavior/neurological MP:0005386 9.89 CALCA FAAH FOS IL6 OPRK1 OPRL1
8 integument MP:0010771 9.53 CALCA FAAH FOS IL6 OPRK1 OPRL1
Sources

Drugs & Therapeutics for Agnosia

About this section

Drugs for Agnosia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 171)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
2
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
3
Nalbuphine Approved Phase 4 20594-83-6 5311304
4
Cisatracurium Approved, Investigational Phase 4 96946-41-7 62887
5
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9
6
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
7
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
8
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
9
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
10
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
11
Norepinephrine Approved Phase 4 51-41-2 439260
12
Codeine Approved, Illicit Phase 4 76-57-3, 6854-40-6 5284371 5362471
13
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
14
Butorphanol Approved, Illicit, Vet_approved Phase 4 58786-99-5, 42408-82-2 5361092
15
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
16
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
17
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
18
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
19
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
21
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
22
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
24
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
25
Acetaminophen Approved Phase 4 103-90-2 1983
26
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
27
Morphine Approved, Investigational Phase 4 57-27-2 5288826
28
Remifentanil Approved Phase 4 132875-61-7 60815
29
Nefopam Approved, Investigational Phase 4 13669-70-0 4450
30
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
31
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
32
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
33
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
34
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
35
Butyric Acid Experimental, Investigational Phase 4 107-92-6 264
36
Trichostatin A Experimental Phase 4 58880-19-6 5562 444732
37 Neuromuscular Blocking Agents Phase 4
38 Opiate Alkaloids Phase 4
39 Cola Phase 4
40 Dexamethasone 21-phosphate Phase 4
41 HIV Protease Inhibitors Phase 4
42 BB 1101 Phase 4
43
protease inhibitors Phase 4
44 Excitatory Amino Acid Antagonists Phase 4
45 Anesthetics, Dissociative Phase 4
46 Adrenergic alpha-Agonists Phase 4
47 Adrenergic Agonists Phase 4
48 Adrenergic Agents Phase 4
49 Hypnotics and Sedatives Phase 4
50 Antineoplastic Agents, Hormonal Phase 4

Interventional clinical trials:

(show top 50) (show all 249)
# Name Status NCT ID Phase Drugs
1 Effect of Dexmedetomidine Combined With Dezocine and Flubiprofen for Postoperative Intravenous Patient Controlled Analgesia After Colorectal Surgery Unknown status NCT03014713 Phase 4 Dezocine;Flubiprofen;Dexmedetomidine
2 Intravenous Versus Caudal Supplementation of Ketamine for Postoperative Pain Control in Children,A Double-blind Controlled Clinical Trial. Unknown status NCT00532662 Phase 4 S(+)-ketamine
3 Analgesia After Total Knee Arthroplasty: Randomized Controlled Trial Comparing (a) Periarticular Multimodal Technique With (B) Continuous Femoral Nerve Block + Posterior Capsular Injection Unknown status NCT00869037 Phase 4 Periarticular Injection;CFNB + Posterior Capsular Injection
4 Ketamine and Postoperative Analgesia in Children Unknown status NCT00200564 Phase 4 ketamine
5 The Efficacy and Optimal Dose of Sufentanil in Patient Controlled Analgesia After Moderate Surgery Unknown status NCT02503826 Phase 4 Sufentanil;Midazolam;propofol;cisatracurium
6 Postoperative Patient Controlled Epidural Analgesia After Total Knee Arthroplasty With 2ug/ml Fentanyl Combine With 0.2% Ropivacaine or 0.2% Levobupivcaine Unknown status NCT01158586 Phase 4 Levobupivacaine
7 Multimodal Opiate-sparing Analgesia Versus Traditional Opiate Based Analgesia After Cardiac Surgery, a Randomized Controlled Trial Completed NCT01966172 Phase 4 Ibuprofen;Gabapentin;Morphine;Paracetamol
8 Evaluation of the Effect of Adding Magnesium Sulfate Infusion to Ketamine Infusion on Improvement of the Analgesic Efficacy in Cancer Breast Surgeries. Completed NCT04111848 Phase 4 Ketamine;ketamine and magnesium
9 Intravenous and Intraperitoneal Lignocaine for Perioperative Analgesia in Laparoscopic Colon Resections Completed NCT03105193 Phase 4 IV Saline bolus and infusion;IP Saline bolus and infusion;IV lignocaine bolus and infusion;IP Lignocaine bolus and infusion
10 The Combination Effect of Dexmedetomidine and Morphine in Postoperative Patient-Controlled Analgesia Completed NCT00800826 Phase 4 dexmedetomidine
11 Intraoperative and Postoperative Analgesia for Laparoscopic Surgery. Completed NCT00772187 Phase 4 morphine;intrathecal analgesia (morphine);general anesthesia (fentanyl)
12 Postoperative Pain and Systemic Inflammatory Stress Response (SIRS) After Preoperative Analgesia With Clonidine or Levobupivacaine Completed NCT00860899 Phase 4 clonidine, levobupivacaine
13 Comparison of Intrathecal Morphine, Epidural Bupivacaine With Sufentanil and Systemic Patient Controlled Analgesia With Morphine for Analgesia After Colorectal Surgery: Prospective Randomised Study. Completed NCT03007121 Phase 4 Morphine intrathecal;Bupivacaine + Sufentanil epidural;Morphine intravenous
14 Femoral Nerve Block Using 0.25% Versus 0.5% Bupivacaine for Analgesia After Arthroscopic Anterior Cruciate Ligament Reconstruction Completed NCT01593566 Phase 4 0.25% Bupivacaine;0.5% Bupivacaine
15 A Randomized Controlled Comparison of Different Dose Combinations of Bupivacaine and Sufentanil on Epidural Analgesia Onset Time and Adverse Reactions During Labor Completed NCT03395600 Phase 4 B1S5;B125S5;B1S10
16 Intravenous Continuous Infusion of Dexamethasone Plus Tramadol Combined With Standard Morphine Patient-Controlled Analgesia After Total Abdominal Hysterectomy Completed NCT00564603 Phase 4 Dexamethasone Sodium Phosphate Injection
17 Levobupivacaine for Epidural Analgesia in Labour Completed NCT00929682 Phase 4 Randomization between two referenced treatments
18 Efficacy Of Scalp Block And Ultrasound Guided TAP Block With Clonidine As Adjuvant To Ropivacaine Versus Intravenous Fentanyl On Intraoperative Hemodynamics And Perioperative Analgesia In Abdominal Bone Flap Cranioplasties: A Prospective, Randomised, Double Blind Study Completed NCT03667352 Phase 4 Intravenous Fentanyl
19 Extension of the Analgesia of an Interscalene Block of the Brachial Plexus by Combined Injection of Dexamethasone and Dexmedetomidine, After Arthroscopic Shoulder Surgery: Randomized, Controlled, Double-blind Trial Completed NCT04394481 Phase 4 Dexmedetomidine;Ropivacaine;Dexamethasone
20 Does Postoperative Administration of Oral Oxycodone With/Without Naloxone, Reduce the Duration of Epidural Analgesia in Patients Undergoing Cystectomy Without Impairing Its Benefits? A Randomized, Double Blind Controlled Trial Completed NCT02516059 Phase 4 oxycodone/naloxone;Oxycodone;Placebo
21 Analgesia Effects of Intravenous Ketamine After Spinal Anesthesia for Non-elective Cesarean Section Completed NCT03450499 Phase 4 Ketamine;Placebo
22 Analgesic Efficacy of Ropivacaine Alone or in Combination With Adjuvants on Post-operative Analgesia Following Video-Assisted Thoracoscopic Surgery (VATS) - A Randomized Controlled Trial. Recruiting NCT03809442 Phase 4 Ropivacaine + Ketamine;Ropivacaine + Tramadol;Ropivacaine + Midazolam;Ropivacaine + Dexmedetomidine;Ropivacaine + Dexamethasone;Ropivacaine
23 Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation: A Dose-exploration and Effectiveness Study Recruiting NCT04436224 Phase 4 Hydromorphone;Fentanyl;Butorphanol
24 Comparative Study Between Dexmedetomidine and Fentanyl as Adjuvants to Bupivacaine for Post-operative Epidural Analgesia in Abdominal Surgeries Recruiting NCT05323214 Phase 4 Control Analgesic regimen;Fentanyl Analgesic regimen;Dexmedetomidine Analgesic regimen
25 Evaluation of Plasma Concentrations of Intravenous Lidocaine and Epidural Ropivacaine When Used in Combination in Major Abdominal Surgery Recruiting NCT05368753 Phase 4 Lidocain;ropivacaine
26 Effects of Individualized Opioid Analgesia Versus Conventional Opioid Analgesia After Adenotonsillectomy in Children Recruiting NCT04527393 Phase 4 Individualized oral morphine;Conventional oral morphine
27 Posterior Transversus Abdominis Plane Block Versus Erector Spinae Plane Block as a Part of Multimodal Analgesia in Patients Undergoing Percutaneous Nephrolithotomy. A Prospective Randomized Clinical Trial Recruiting NCT05448495 Phase 4
28 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
29 Impact of Preoperative Aripiprazole on Postoperative Analgesia in Laparoscopic Hysterectomy: A Randomized Controlled Clinical Trial Active, not recruiting NCT05103410 Phase 4 ARIPiprazole 30 MG;Placebo
30 Efficacy of Combined US-Guided Supraclavicular Block and Interscalene Analgesia Versus an Intercostobrachial Nerve Block Versus PCA With Fentanyl on Preventing Tourniquet Pain in Forearm Surgery: A Randomized Clinical Trial Not yet recruiting NCT05602636 Phase 4 bupivacaine, midazolam
31 Transversus Abdominis Plane Block Plus Quadratus Lumborum Block or Retrolaminar Block of Multiple Injections for Postoperative Analgesia Following Laparoscopic Colorectal Surgery: A Randomized, Double-blind, Controlled Trial Not yet recruiting NCT05416866 Phase 4
32 Prospective, Controlled Versus Placebo, Randomized, Double-blind Study, Evaluating the Value of Non-opioid Analgesic Combination (Based on Paracetamol, Nefopam, Ketoprofen) for Postoperative Analgesia. Terminated NCT01882530 Phase 4 Paracetamol;Nefopam;Ketoprofen;Morphine
33 A Randomized, Open-label, Multicenter, Parallel-group Study to Compare the Efficacy, Safety and Resource Utilization of a Remifentanil/Propofol Analgesia/Sedation Regimen Versus a Sufentanil/Propofol Analgesia/Sedation Regimen in Mechanically Ventilated Intensive Care Patients Requiring Analgesia and Sedation for up to 7 Days Terminated NCT00421720 Phase 4 Sufentanil;Remifentanil
34 Use of Oral Pregabalin as Preemptive Analgesia in Abdominal Hysterectomy: Evaluation of Postoperative Pain and Opioid Consumption Terminated NCT04495374 Phase 4 Pregabalin 300mg
35 The Effect of Pectoralis Block on Analgesia After Simple Mastectomy Withdrawn NCT03143530 Phase 4 Normal saline injection;Ropivacaine Injection
36 Laparoscopic Guided Transversus Abdominis Plane Block for Postoperative Analgesia After Pediatric Laparoscopic Surgery. Unknown status NCT03388671 Phase 2, Phase 3 Bupivacaine
37 Is Continuous Wound Infusion With Ropivacaine Better Than Intrathecal Morphine for Post-caesarean Analgesia? A Prospective, Randomized, Controlled, Double Blinded Study Completed NCT02264821 Phase 3 ropivacaine infiltration;intrathecal morphine;placebo
38 Post-Operatory Analgesia in Newborn Infants: a Comparative Study of Fentanyl Versus Tramadol Completed NCT00713726 Phase 3 FentanyL;Tramadol
39 Analgesia for Neonatal Circumcision: A Randomized Controlled Clinical Trial of EMLA Versus Combination of EMLA, Sucrose and Dorsal Penile Nerve Block or Ring Block Completed NCT02990364 Phase 3 Sucrose;Lidocaine;EMLA Topical Product
40 Comparison of Perioperative Analgesia Between Intravenous Paracetamol and Fentanyl for Rigid Hysteroscopy Completed NCT04762147 Phase 3 paracetamol, the group P;fentanyl, group-F administered as an active comparator
41 A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK21542 Injection for Postoperative Analgesia of Subjects Undergoing Elective Laparoscopic Surgery Under General Anesthesia Completed NCT04738357 Phase 3 HSK21542;Placebo
42 Comparative Study Between Intraperitoneal Administration of Either Bupivacaine and Tramadol Versus Bupivacaine and Dexmedetomedine for Analgesia After Abdominal Laparoscopic Cancer Surgeries. A Prospective Randomized Pilot Study Completed NCT04813016 Phase 2, Phase 3 Tramal 1;Tramal 2;Dexmedetomidine 1;dexmedetomidine 2
43 Epidural Analgesia During Labour Randomized Clinical Trial Comparing Patient Controlled Epidural Analgesia Versus Patient Intermittent Epidural Boluses With Levobupivacaine Completed NCT03133091 Phase 3 PIEB: Patient Intermittent Epidural Boluses;PCEA: Patient Controlled Epidural Analgesia
44 Continuous Regional Analgesia After Total Knee Arthroplasty. Normal Saline or Dextrose 5% in Water as Fluid Medium for Pre-Placement Expansion in Order to Facilitate the Catheter Passing Completed NCT00337597 Phase 3
45 A Phaseâ…¡/ â…¢ Seamless Study to Evaluate Efficacy and Safety of Paracetamol Injection as Adjuvant to Morphine-based Postoperative Analgesia-Multicentered, Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT02811991 Phase 2, Phase 3 Paracetamol injection;Normal Saline injection;Morhpine PCA
46 Ultrasound-guided Erector Spinae Plane Block Versus Paravertebral Block for Perioperative Analgesia, a Randomized Double Blinded Controlled Trial Completed NCT05448469 Phase 3 conventional analgesia
47 COMBINATION OF CONTINUOUS FEMORAL BLOCK AND INTRAVENOUS PARECOXIB FOR POSTOPERATIVE ANALGESIA AFTER TOTAL KNEE ARTHROPLASTY. A DOUBLE BLIND PROSPECTIVE STUDY. Completed NCT02185924 Phase 2, Phase 3 Parecoxib;CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%;N/S 0.9%
48 Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 Completed NCT02333305 Phase 3
49 Neuroimaging Study of Dexmedetomidine-Induced Analgesia Recruiting NCT04656470 Phase 2, Phase 3 Dexmedetomidine
50 A Non-Inferiority Randomized Trial Comparing the Impact of Thoracic Epidural Analgesia Versus Surgical Site Infiltration With Liposomal Bupivicaine on the Postoperative Recovery of Patients Following Open Gynecologic Surgery Recruiting NCT04117074 Phase 3 Liposomal bupivacaine

Search NIH Clinical Center for Agnosia

Cochrane evidence based reviews: agnosia

Sources

Genetic Tests for Agnosia

About this section
Sources

Anatomical Context for Agnosia

About this section

Organs/tissues related to Agnosia:

MalaCards : Temporal Lobe, Brain, Cortex, Breast, Lung, Heart, Parietal Lobe
Sources

Publications for Agnosia

About this section

Articles related to Agnosia:

(show top 50) (show all 2111)
# Title Authors PMID Year
1
Whole-genome sequencing of patients with rare diseases in a national health system. 5
32581362 2020
2
Prenatal Diagnosis and Neurodevelopmental Outcome in Isolated Cerebellar Hypoplasia of Suspected Hemorrhagic Etiology: a Retrospective Cohort Study. 62
34799840 2022
3
Ictal apnea: A prospective monocentric study in patients with epilepsy. 62
36057450 2022
4
The human brain networks mediating the vestibular sensation of self-motion. 62
36332321 2022
5
Tactually-related cognitive impairments: sharing of neural substrates across associative tactile agnosia, agraphesthesia, and kinesthetic reading difficulty. 62
36336779 2022
6
Temporopolar regions of the human brain. 62
36331542 2022
7
Right hemi-alexia. 62
36370599 2022
8
Allochiria for spatial landmarks as the presenting feature of posterior cortical atrophy. 62
36370598 2022
9
The making of a syndrome: Gerstmann's patients before Gerstmann syndrome. 62
35998548 2022
10
Cytotoxic lesions of the corpus callosum after COVID-19 vaccination. 62
35809100 2022
11
The rehabilitation of object agnosia and prosopagnosia: A systematic review. 62
36155537 2022
12
Distinguishing transient from persistent tactile agnosia after partial anterior circulation infarcts - Behavioral and neuroimaging evidence for white matter disconnection. 62
36126517 2022
13
Pure word deafness: a case report of an atypical manifestation of Alzheimer's disease. 62
35710959 2022
14
De novo truncating NOVA2 variants affect alternative splicing and lead to heterogeneous neurodevelopmental phenotypes. 62
35607920 2022
15
Functional Neurological Symptom Disorder Manifesting as Auditory Verbal Agnosia in a 19-Year-Old Patient. 62
36120270 2022
16
Auditory Agnosia in Autoimmune Encephalitis. 62
35929447 2022
17
Narrative care: Unpacking pandemic paradoxes. 62
34541743 2022
18
The adult developmental coordination disorders/dyspraxia checklist - German: adapted factor structure for the differentiation of DCD and ADHD. 62
35550942 2022
19
Hippotherapy in neurodevelopmental disorders: a narrative review focusing on cognitive and behavioral outcomes. 62
33949903 2022
20
Unusual complication of Herpes simplex encephalitis: complete Klüver-Bucy syndrome. 62
35817482 2022
21
Clinical Screening for Posterior Cortical Atrophy. 62
35639011 2022
22
A novel variant in SMG9 causes intellectual disability, confirming a role for nonsense-mediated decay components in neurocognitive development. 62
35087184 2022
23
The Role of Motor Coordination, ADHD-Related Characteristics and Temperament among Mothers and Infants in Exclusive Breastfeeding: A Cohort Prospective Study. 62
35564903 2022
24
Motor signature of autism spectrum disorder in adults without intellectual impairment. 62
35538115 2022
25
Reflected image processing abnormalities in dementia - a case series and review. 62
35531907 2022
26
Author Response: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease. 62
35410920 2022
27
Reader Response: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease. 62
35410919 2022
28
Aftereffects to Prism Exposure without Adaptation: A Single Case Study. 62
35448011 2022
29
Predictive value of brain MRI at term-equivalent age in extremely preterm children on neurodevelopmental outcome at school-age. 62
34661873 2022
30
The role of Augmentative and Alternative Communication in Speech and Language Therapy: A mini review. 62
35320253 2022
31
Semantic Feature Extraction Using SBERT for Dementia Detection. 62
35204032 2022
32
Moyamoya disease with Sjogren disease and autoimmune thyroiditis presenting with left intracranial hemorrhage after messenger RNA-1273 vaccination: A case report. 62
35147099 2022
33
Compound genetic etiology in a patient with a syndrome including diabetes, intellectual deficiency and distichiasis. 62
35227307 2022
34
False recognition/misidentification of unfamiliar person after cerebral infarction: A case report. 62
35051711 2022
35
[Apperceptive and associative visual object agnosia in patients with acute ischemic stroke]. 62
36036139 2022
36
[Frontotemporal dementia with cortico-basal syndrome]. 62
35271245 2022
37
[Uncommon variants of speech disorder in children: congenital bilateral perisylvian syndrome]. 62
36170094 2022
38
Supporting the mental health of children with speech, language and communication needs: The views and experiences of parents. 62
36124076 2022
39
Case Report: Late-Onset Mitochondrial Disease Uncovered by Metformin Use in a Patient With Acute Verbal Auditory Agnosia. 62
35401420 2022
40
Case Report: SMART ANTON: Anton-Babinski Syndrome in Stroke-Like Migraine Attacks (SMART) After Radiation Therapy: Two Rare Syndromes, One Case. 62
35832180 2022
41
Semaphorin-Plexin Signaling: From Axonal Guidance to a New X-Linked Intellectual Disability Syndrome. 62
34740135 2022
42
Novel Biallelic Variant in the BRAT1 Gene Caused Nonprogressive Cerebellar Ataxia Syndrome. 62
35360849 2022
43
Cortical disorders of speech processing: Pure word deafness and auditory agnosia. 62
35964993 2022
44
Evaluation of cognitive deficits in patients infected with COVID-19. 62
35113443 2022
45
Visual objects and their colors. 62
35964971 2022
46
A connectivity model of the anatomic substrates underlying Gerstmann syndrome. 62
35706977 2022
47
"Where am I?" A snapshot of the developmental topographical disorientation among young Italian adults. 62
35857777 2022
48
Mobile EEG reveals functionally dissociable dynamic processes supporting real-world ambulatory obstacle avoidance: Evidence for early proactive control. 62
33465827 2021
49
Oral dyspraxia in self-limited epilepsy with centrotemporal spikes: a comparative study with a control group. 62
34816971 2021
50
Early diagnosis of the learning disabilities in kids using a computer game-based solution. 62
34784486 2021
Sources

Variations for Agnosia

About this section

ClinVar genetic disease variations for Agnosia:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SIL1 NC_000005.10:g.139189727_139201554del DEL Pathogenic
 812923 GRCh37: 5:138525416-138537243
GRCh38:
Sources

Expression for Agnosia

About this section
Search GEO for disease gene expression data for Agnosia.
Sources

Pathways for Agnosia

About this section

Pathways related to Agnosia according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
GPCR downstream signalling 66
Show member pathways
 13.25 CALCA OPRK1 OPRL1 OPRM1 OXT PDYN
2
Signal Transduction 66
13.11 TAC1 POMC PNOC PDYN OXT OPRM1
3
Class A/1 (Rhodopsin-like receptors) 66
Show member pathways
 12.4 TAC1 POMC PNOC PDYN OXT OPRM1
4
Neuroscience 3
12.33 SCN9A SAG POMC OPRM1 CALCA
5
Myometrial relaxation and contraction pathways 74
Show member pathways
 12.26 OXT IL6 FOS CALCA
6
Spinal cord injury 74
11.73 PDYN IL6 FOS
7
Glucocorticoid receptor regulatory network 61
11.52 POMC IL6 FOS
8
Interleukin-4 and Interleukin-13 signaling 66
11.49 POMC OPRM1 IL6 FOS
9
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.26 IL6 FOS CALCA
10
Serotonin and anxiety 74
Show member pathways
 10.9 TRPV1 POMC FOS
11
Chronic hyperglycemia impairment of neuron function 74
9.85 TRPV1 TRPA1
Sources

GO Terms for Agnosia

About this section

Cellular components related to Agnosia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.18 OPRK1 OPRL1 OPRM1 SCN9A TRPA1 TRPV1
2 plasma membrane GO:0005887 10.18 OPRK1 OPRL1 OPRM1 SCN9A TRPA1 TRPV1
3 axon terminus GO:0043679 9.73 PNOC PDYN OPRK1
4 neuronal cell body GO:0043025 9.7 TRPV1 TAC1 PNOC PDYN OPRK1 CALCA
5 neuron projection GO:0043005 9.36 TRPV1 SCN9A OPRM1 OPRL1 OPRK1 FOS

Biological processes related to Agnosia according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.44 TYROBP SAG POMC PNOC OXT OPRM1
2 inflammatory response GO:0006954 10.31 TRPV1 TAC1 SCN9A IL6 FOS CALCA
3 positive regulation of cytosolic calcium ion concentration GO:0007204 10.11 TRPV1 TAC1 OXT OPRM1 CALCA
4 response to activity GO:0014823 10.09 OXT IL6 FOS
5 response to cold GO:0009409 10.08 FOS SCN9A TRPA1
6 cellular response to nerve growth factor stimulus GO:1990090 10.05 TRPV1 TAC1 CALCA
7 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 10.03 OPRM1 OPRL1 OPRK1
8 response to heat GO:0009408 10.03 TRPV1 SCN9A CALCA
9 response to cocaine GO:0042220 9.96 OXT OPRM1 OPRK1
10 negative regulation of blood pressure GO:0045776 9.95 OXT OPRL1 CALCA
11 eating behavior GO:0042755 9.92 OXT OPRM1 OPRL1 OPRK1
12 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0106072 9.91 OPRM1 OPRL1
13 estrous cycle GO:0044849 9.91 OPRK1 OPRL1 OPRM1
14 regulation of sensory perception of pain GO:0051930 9.91 OXT OPRM1 OPRL1 OPRK1
15 thermoception GO:0050955 9.89 TRPA1 TRPV1
16 conditioned place preference GO:1990708 9.88 OPRK1 OPRL1
17 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.88 TRPV1 SCN9A CALCA
18 G protein-coupled opioid receptor signaling pathway GO:0038003 9.88 OPRM1 OPRL1 OPRK1
19 neuropeptide signaling pathway GO:0007218 9.86 CALCA OPRK1 OPRL1 OPRM1 PDYN PNOC
20 sensory perception GO:0007600 9.85 PNOC PDYN OPRM1 OPRL1 OPRK1
21 detection of chemical stimulus involved in sensory perception of pain GO:0050968 9.84 TRPV1 TRPA1
22 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.83 OPRK1 OPRM1
23 positive regulation of gastric acid secretion GO:0060454 9.81 OPRL1 TRPV1
24 response to pain GO:0048265 9.8 CALCA TAC1 TRPA1 TRPV1
25 behavior GO:0007610 9.62 OPRL1 OPRK1
26 postsynaptic signal transduction GO:0098926 9.49 OPRK1 OPRM1
27 sensory perception of pain GO:0019233 9.44 TRPV1 TRPA1 TAC1 SCN9A OPRM1 OPRL1

Molecular functions related to Agnosia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calcium-release channel activity GO:0015278 9.62 TRPV1 TRPA1
2 opioid receptor binding GO:0031628 9.56 PNOC PDYN
3 opioid peptide activity GO:0001515 9.46 PNOC PDYN
4 neuropeptide binding GO:0042923 9.43 OPRM1 OPRL1 OPRK1
5 G protein-coupled opioid receptor activity GO:0004985 8.92 OPRM1 OPRL1 OPRK1
Sources

Sources for Agnosia

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....